Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H31NO |
Molecular Weight | 325.4876 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)N(CC[C@H](C1=CC=CC=C1)C2=C(O)C=CC(C)=C2)C(C)C
InChI
InChIKey=OOGJQPCLVADCPB-HXUWFJFHSA-N
InChI=1S/C22H31NO/c1-16(2)23(17(3)4)14-13-20(19-9-7-6-8-10-19)21-15-18(5)11-12-22(21)24/h6-12,15-17,20,24H,13-14H2,1-5H3/t20-/m1/s1
Molecular Formula | C22H31NO |
Molecular Weight | 325.4876 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Tolterodine is competitive muscarinic receptors M3 and M2 antagonist. It was sold under trade names detrol for the treatment of overactive bladder with symptoms of urge urinary incontinence. Both urinary bladder contraction and salivation are mediated via cholinergic muscarinic receptors. After oral administration, tolterodine is metabolized in the liver, resulting in the formation of the 5-hydroxymethyl derivative, a major pharmacologically active metabolite. The 5-hydroxymethyl metabolite, which exhibits an antimuscarinic activity similar to that of tolterodine, contributes significantly to the therapeutic effect. Both tolterodine and the 5-hydroxymethyl metabolite exhibit a high specificity for muscarinic receptors, since both show negligible activity and affinity for other neurotransmitter receptors and other potential cellular targets, such as calcium channels. Tolterodine has a pronounced effect on bladder function. The main effects of tolterodine at 1 and 5 hours were an increase in residual urine, reflecting an incomplete emptying of the bladder, and a decrease in detrusor pressure. These findings are consistent with an antimuscarinic action on the lower urinary tract.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL245 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16465186 |
|||
Target ID: CHEMBL211 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16465186 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | DETROL Approved UseTolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see CLINICAL STUDIES (14) Launch Date8.9078399E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.8 μg/L |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLTERODINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: HIGH-FAT |
|
2.3 μg/L |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLTERODINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED |
|
1.6 μg/L |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLTERODINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
10 μg/L |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLTERODINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
19 μg/L |
4 mg 2 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOLTERODINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2.6 μg/L |
4 mg 2 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOLTERODINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
23 μg × h/L |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLTERODINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: HIGH-FAT |
|
27 μg × h/L |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLTERODINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.1 h |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLTERODINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: HIGH-FAT |
|
7.9 h |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLTERODINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED |
|
2 h |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLTERODINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
6.5 h |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLTERODINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
9.6 h |
4 mg 2 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOLTERODINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2.2 h |
4 mg 2 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TOLTERODINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
2 mg 2 times / day multiple, oral Recommended Dose: 2 mg, 2 times / day Route: oral Route: multiple Dose: 2 mg, 2 times / day Sources: Page: p.804 |
unhealthy, 20-93 n = 507 Health Status: unhealthy Condition: Overactive bladder Age Group: 20-93 Sex: M+F Population Size: 507 Sources: Page: p.804 |
Disc. AE: Dry mouth... AEs leading to discontinuation/dose reduction: Dry mouth (2.4%) Sources: Page: p.804 |
4 mg 2 times / day multiple, oral Highest studied dose Dose: 4 mg, 2 times / day Route: oral Route: multiple Dose: 4 mg, 2 times / day Sources: Page: p.997 |
unhealthy, 52 n = 58 Health Status: unhealthy Condition: Overactive bladder Age Group: 52 Sex: M+F Population Size: 58 Sources: Page: p.997 |
Disc. AE: Urinary retention... AEs leading to discontinuation/dose reduction: Urinary retention (6.9%) Sources: Page: p.997 |
2 mg 2 times / day multiple, oral Recommended Dose: 2 mg, 2 times / day Route: oral Route: multiple Dose: 2 mg, 2 times / day Sources: Page: p.11 |
unhealthy n = 986 Health Status: unhealthy Condition: Overactive bladder Sex: M+F Population Size: 986 Sources: Page: p.11 |
Disc. AE: Dry mouth, Dizziness... AEs leading to discontinuation/dose reduction: Dry mouth (1%) Sources: Page: p.11Dizziness (common) Headache (common) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Dry mouth | 2.4% Disc. AE |
2 mg 2 times / day multiple, oral Recommended Dose: 2 mg, 2 times / day Route: oral Route: multiple Dose: 2 mg, 2 times / day Sources: Page: p.804 |
unhealthy, 20-93 n = 507 Health Status: unhealthy Condition: Overactive bladder Age Group: 20-93 Sex: M+F Population Size: 507 Sources: Page: p.804 |
Urinary retention | 6.9% Disc. AE |
4 mg 2 times / day multiple, oral Highest studied dose Dose: 4 mg, 2 times / day Route: oral Route: multiple Dose: 4 mg, 2 times / day Sources: Page: p.997 |
unhealthy, 52 n = 58 Health Status: unhealthy Condition: Overactive bladder Age Group: 52 Sex: M+F Population Size: 58 Sources: Page: p.997 |
Dry mouth | 1% Disc. AE |
2 mg 2 times / day multiple, oral Recommended Dose: 2 mg, 2 times / day Route: oral Route: multiple Dose: 2 mg, 2 times / day Sources: Page: p.11 |
unhealthy n = 986 Health Status: unhealthy Condition: Overactive bladder Sex: M+F Population Size: 986 Sources: Page: p.11 |
Dizziness | common Disc. AE |
2 mg 2 times / day multiple, oral Recommended Dose: 2 mg, 2 times / day Route: oral Route: multiple Dose: 2 mg, 2 times / day Sources: Page: p.11 |
unhealthy n = 986 Health Status: unhealthy Condition: Overactive bladder Sex: M+F Population Size: 986 Sources: Page: p.11 |
Headache | common Disc. AE |
2 mg 2 times / day multiple, oral Recommended Dose: 2 mg, 2 times / day Route: oral Route: multiple Dose: 2 mg, 2 times / day Sources: Page: p.11 |
unhealthy n = 986 Health Status: unhealthy Condition: Overactive bladder Sex: M+F Population Size: 986 Sources: Page: p.11 |
PubMed
Title | Date | PubMed |
---|---|---|
Cost-Effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective. | 2001 Dec |
|
The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel. | 2001 Nov |
|
Tolterodine: an overview. | 2001 Nov |
|
Which muscarinic receptor is important in the bladder? | 2001 Nov |
|
Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder. | 2001 Oct |
|
[Continence problems after radical prostatectomy: medical treatment]. | 2001 Sep |
|
Effect of tolterodine on the anticoagulant actions and pharmacokinetics of single-dose warfarin in healthy volunteers. | 2002 |
|
Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). | 2002 |
|
Tolterodine: selectivity for the urinary bladder over the eye (as measured by visual accommodation) in healthy volunteers. | 2002 |
|
Gateways to Clinical Trials. | 2002 Apr |
|
A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT). | 2002 Apr |
|
Tolterodine: a safe and effective treatment for older patients with overactive bladder. | 2002 Apr |
|
Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. | 2002 Dec |
|
Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. | 2002 Dec |
|
Advances in drug delivery: improved bioavailability and drug effect. | 2002 Dec |
|
Methodologic shortcomings inherent in a post-hoc analysis. | 2002 Dec |
|
Medication update. | 2002 Feb |
|
Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. | 2002 Jan |
|
Gateways to clinical trials. | 2002 Jan-Feb |
|
Comparison of laparoscopic Burch and tension-free vaginal tape in treating stress urinary incontinence in obese patients. | 2002 Jan-Mar |
|
Current pharmacotherapeutic strategies for overactive bladder. | 2002 Jul |
|
Gateways to clinical trials. | 2002 Jul-Aug |
|
The overactive bladder: a nursing perspective. | 2002 Jun |
|
Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors. | 2002 Jun |
|
Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. | 2002 Mar |
|
Pharmacotherapy of the overactive bladder and advances in drug delivery. | 2002 Mar |
|
Muscarinic receptor antagonist-induced lenticular opacity in rats. | 2002 Mar |
|
Achieving bladder control. Treatment in the primary care setting. | 2002 May |
|
Tolterodine and its active 5-hydroxymethyl metabolite: pure muscarinic receptor antagonists. | 2002 May |
|
Tolterodine-associated acute mixed liver injury. | 2002 May |
|
Assessment and conservative management of the neuropathic bladder. | 2002 May |
|
Muscarinic receptor subtypes and management of the overactive bladder. | 2002 Nov |
|
Conservative management in neurogenic bladder dysfunction. | 2002 Nov |
|
Functional role of central muscarinic receptors for micturition in normal conscious rats. | 2002 Nov |
|
Different responses to drugs against overactive bladder in detrusor muscle of pig, guinea pig and mouse. | 2002 Nov 1 |
|
The newer antimuscarinic drugs: bladder control with less dry mouth. | 2002 Oct |
|
Pharmacologic treatment for detrusor overactivity. | 2002 Oct |
|
Treatment of overactive bladder: the Antimuscarinic Clinical Effectiveness Trial. | 2002 Oct |
|
The subtypes of muscarinic receptors for neurogenic bladder contraction in rats. | 2002 Oct 4 |
|
Gateways to Clinical Trials. | 2002 Sep |
|
Characterization of a new muscarinic receptor antagonist PNU-171990 in guinea pig, cat and human smooth muscle. | 2002 Sep 13 |
|
Treatment can lead to a long dry spell. | 2002 Spring |
|
New treatment options for overactive bladder and incontinence. | 2002 Summer |
|
Effects of ATP-sensitive K+ channel openers and tolterodine on involuntary bladder contractions in a pig model of partial bladder outlet obstruction. | 2003 |
|
25-Hydroxylation of vitamin D3 in primary cultures of pig hepatocytes: evidence for a role of both CYP2D25 and CYP27A1. | 2003 Apr 11 |
|
A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder. | 2003 Feb |
|
In vivo evaluation of the potency and bladder-vascular selectivity of the ATP-sensitive potassium channel openers (-)-cromakalim, ZD6169 and WAY-133537 in rats. | 2003 Feb |
|
Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. | 2003 Jan |
|
Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence. | 2003 Jan |
|
The use of tolterodine in children after oxybutynin failure. | 2003 Mar |
Sample Use Guides
The initial recommended dose of DETROL (tolterodine tartrate tablets) is 2 mg twice daily. The dose may be lowered to 1 mg twice daily based on individual response and tolerability. For patients with significantly reduced hepatic or renal function or who are currently taking drugs that are potent inhibitors of CYP3A4, the recommended dose of DETROL is 1 mg twice daily
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9200560
It was compared the antimuscarinic properties of tolterodine with those of oxybutynin, in vitro and in vivo. Tolterodine effectively inhibited carbachol-induced contractions of isolated strips of urinary bladder from guinea pigs (K(B) 3.0 nM; pA2 8.6; Schild slope 0.97) and humans (K(B) 4.0 nM; pA2 8.4; Schild slope 1.04) in a concentration-dependent, competitive manner. The affinity of tolterodine was similar to that derived for oxybutynin (K(B) 4.4 nM; pA2 8.5; Schild slope 0.89) in the guinea-pig bladder. Radioligand binding data showed that tolterodine bound with high affinity to muscarinic receptors in urinary bladder (K(i) 2.7 nM), heart (K(i) 1.6 nM), cerebral cortex (K(i) 0.75 nM) and parotid gland (K(i) 4.8 nM) from guinea pigs and in urinary bladder from humans (K(i) 3.3 nM). The combined in vitro and in vivo data on tolterodine and oxybutynin may indicate either that muscarinic M3/m3 receptors in glands are more sensitive to blockade than those in bladder smooth muscle, or that muscarinic M2/m2 receptors contribute to bladder contraction.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 18:00:50 UTC 2022
by
admin
on
Fri Dec 16 18:00:50 UTC 2022
|
Record UNII |
WHE7A56U7K
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000000125
Created by
admin on Fri Dec 16 18:00:50 UTC 2022 , Edited by admin on Fri Dec 16 18:00:50 UTC 2022
|
||
|
LIVERTOX |
NBK548516
Created by
admin on Fri Dec 16 18:00:50 UTC 2022 , Edited by admin on Fri Dec 16 18:00:50 UTC 2022
|
||
|
NDF-RT |
N0000175700
Created by
admin on Fri Dec 16 18:00:50 UTC 2022 , Edited by admin on Fri Dec 16 18:00:50 UTC 2022
|
||
|
WHO-VATC |
QG04BD07
Created by
admin on Fri Dec 16 18:00:50 UTC 2022 , Edited by admin on Fri Dec 16 18:00:50 UTC 2022
|
||
|
NDF-RT |
N0000000125
Created by
admin on Fri Dec 16 18:00:50 UTC 2022 , Edited by admin on Fri Dec 16 18:00:50 UTC 2022
|
||
|
WHO-ATC |
G04BD07
Created by
admin on Fri Dec 16 18:00:50 UTC 2022 , Edited by admin on Fri Dec 16 18:00:50 UTC 2022
|
||
|
NCI_THESAURUS |
C29704
Created by
admin on Fri Dec 16 18:00:50 UTC 2022 , Edited by admin on Fri Dec 16 18:00:50 UTC 2022
|
||
|
NDF-RT |
N0000000125
Created by
admin on Fri Dec 16 18:00:50 UTC 2022 , Edited by admin on Fri Dec 16 18:00:50 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Tolterodine
Created by
admin on Fri Dec 16 18:00:50 UTC 2022 , Edited by admin on Fri Dec 16 18:00:50 UTC 2022
|
PRIMARY | |||
|
WHE7A56U7K
Created by
admin on Fri Dec 16 18:00:50 UTC 2022 , Edited by admin on Fri Dec 16 18:00:50 UTC 2022
|
PRIMARY | |||
|
SUB11180MIG
Created by
admin on Fri Dec 16 18:00:50 UTC 2022 , Edited by admin on Fri Dec 16 18:00:50 UTC 2022
|
PRIMARY | |||
|
DTXSID3023687
Created by
admin on Fri Dec 16 18:00:50 UTC 2022 , Edited by admin on Fri Dec 16 18:00:50 UTC 2022
|
PRIMARY | |||
|
DB01036
Created by
admin on Fri Dec 16 18:00:50 UTC 2022 , Edited by admin on Fri Dec 16 18:00:50 UTC 2022
|
PRIMARY | |||
|
M10954
Created by
admin on Fri Dec 16 18:00:50 UTC 2022 , Edited by admin on Fri Dec 16 18:00:50 UTC 2022
|
PRIMARY | Merck Index | ||
|
CHEMBL1382
Created by
admin on Fri Dec 16 18:00:50 UTC 2022 , Edited by admin on Fri Dec 16 18:00:50 UTC 2022
|
PRIMARY | |||
|
C099041
Created by
admin on Fri Dec 16 18:00:50 UTC 2022 , Edited by admin on Fri Dec 16 18:00:50 UTC 2022
|
PRIMARY | |||
|
2705
Created by
admin on Fri Dec 16 18:00:50 UTC 2022 , Edited by admin on Fri Dec 16 18:00:50 UTC 2022
|
PRIMARY | |||
|
6768
Created by
admin on Fri Dec 16 18:00:50 UTC 2022 , Edited by admin on Fri Dec 16 18:00:50 UTC 2022
|
PRIMARY | |||
|
124937-51-5
Created by
admin on Fri Dec 16 18:00:50 UTC 2022 , Edited by admin on Fri Dec 16 18:00:50 UTC 2022
|
PRIMARY | |||
|
TOLTERODINE
Created by
admin on Fri Dec 16 18:00:50 UTC 2022 , Edited by admin on Fri Dec 16 18:00:50 UTC 2022
|
PRIMARY | |||
|
JJ-43
Created by
admin on Fri Dec 16 18:00:50 UTC 2022 , Edited by admin on Fri Dec 16 18:00:50 UTC 2022
|
PRIMARY | |||
|
443879
Created by
admin on Fri Dec 16 18:00:50 UTC 2022 , Edited by admin on Fri Dec 16 18:00:50 UTC 2022
|
PRIMARY | |||
|
9622
Created by
admin on Fri Dec 16 18:00:50 UTC 2022 , Edited by admin on Fri Dec 16 18:00:50 UTC 2022
|
PRIMARY | |||
|
360
Created by
admin on Fri Dec 16 18:00:50 UTC 2022 , Edited by admin on Fri Dec 16 18:00:50 UTC 2022
|
PRIMARY | |||
|
WHE7A56U7K
Created by
admin on Fri Dec 16 18:00:50 UTC 2022 , Edited by admin on Fri Dec 16 18:00:50 UTC 2022
|
PRIMARY | |||
|
C62083
Created by
admin on Fri Dec 16 18:00:50 UTC 2022 , Edited by admin on Fri Dec 16 18:00:50 UTC 2022
|
PRIMARY | |||
|
119565
Created by
admin on Fri Dec 16 18:00:50 UTC 2022 , Edited by admin on Fri Dec 16 18:00:50 UTC 2022
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
BINDER->LIGAND |
|
||
|
TARGET -> INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
IN-VITRO
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE ACTIVE -> PARENT |
MAJOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|